Onyx Therapeutics sues Dr Reddy’s for patent infringement

US-based Onyx Therapeutics has filed a complaint against India company Dr Reddy’s Laboratories for allegedly infringing a patent covering the drug Kyprolis (carfilzomib).

Kyprolis is a treatment for relapsed or refractory multiple myeloma, which is a type of cancer.

The case, which was filed on Tuesday, November 1 in the US District Court for the District of Delaware, arose after Dr Reddy’s filed an Abbreviated New Drug Application with the Food and Drug Administration seeking approval to manufacture a generic version of the drug.

The patent involved in the case is US number 7,737,112.

Onyx has asked the court for a declaration that Dr Reddy’s has infringed its patent.

The company has also asked the court to award it costs and expenses for bringing the case to court.